**Letter to Editor**

**Title:** Optimal induction treatment regimens for extranodal NK/T-cell lymphoma: lessons learned, challenges, and proposals.

**Running title:** Optimal regimens for ENKTCL

**Authors:** Jing Yang1, Rui-ying Fu1, Xin-di Liu1, Li-qiang Wei1, Liang Wang1,2\*

1Department of Hematology, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China

2Beijing Advanced Innovation Center for Big Data-Based Precision Medicine, Beihang University & Capital Medical University, Beijing Tongren Hospital, Beijing 100730, China

**\*Correspondence to:** Liang Wang, MD, PhD, Department of Hematology, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China. Email: wangliangtrhos@126.com

**Acknowledgments:** This work was financially supported through grants from the National Natural Science Foundation of China (81873450) and the Open Research Fund from Beijing Advanced Innovation Center for Big Data-Based Precision Medicine, Beijing Tongren Hospital, Beihang University & Capital Medical University (grant No. BHTR-KFJJ-202009) to Liang Wang.

**Dear Editor,**

Extranodal NK/T-cell lymphoma (ENKTCL) is a highly aggressive and Epstein-Bar virus (EBV)-associated hematologic malignancy, most prevalent in the Far East and South America[1]. No standard treatment strategy has been defined. It is well recognized that combination of asparaginase-based chemotherapy (CT) and radiotherapy (RT) benefit early-stage ENKTCL. It has been validated that upfront RT can cure most stage I patients of ENKTCL without risk factors, and asparaginase (either L-asparaginase or pegaspargase) is the backbone of chemotherapy for ENKTCL. In recent years, a variety of asparaginase-based regimens have been found to be effective in early-stage ENKTCL, such as GELOX (gemcitabine, oxaliplatin, and asparaginase)[2] or EPOCHL (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and asparaginase)[3], but with different toxicities. Thus, we are wondering how much is too much for early-stage ENKTCL patients, and is intensive chemotherapy really necessary? Moreover, the international T-cell Project reported the updated survival outcomes of a large cohort of worldwide patients with ENKTCL (except Chinese) this year, and more than 60 regimens were used in this report, indicating lack of standard treatment regimens[4]. Compared with survival data of Chinese patients with ENKTCL, the outcomes reported by this international multi-center cohort seem unsatisfactory. Due to very small number of patients enrolled from the USA and no patients from China, it is of importance to show the data from these two large countries, which enable us to depict the real-world data of ENKTCL globally. In this multi-center retrospective study, we compared the efficacy, long-term survival outcomes, and safety profiles between GELOX and EPOCHL regimen in early-stage ENKTCL patients. Meanwhile, the survival outcomes of all-stage patients from China and SEER (Surveillance, Epidemiology, and End Results) database were compared.

A total of 494 patients of ENKTCL with all stages (Ann-Arbor stage I, n=224; stage II, n=168; stage III-IV, n=102) from Beijing Tongren Hospital were included in this study, and all patients received asparaginase-based treatment, among whom 193 patients with stage I-II ENKTCL were treated with 4-6 cycles of GELOX (pegaspargase 2500IU/㎡ d1, gemcitabine 1000mg/㎡ d1,8, oxaliplatin 100mg/㎡ d1, repeated every 3 weeks) or EPOCHL (etoposide 50mg/㎡/d, vincristine 0.5 mg/d, doxorubicin 10mg/㎡/d were administered by continuous intravenous infusion over 96 h d1-4, prednisone 60mg/㎡/d was administered orally on days 1–5, cyclophosphamide 750mg/㎡ was given as an intravenous bolus on day 5, L-asparaginase 10,000 U/d was administered by intravenous infusion on days 6–10 or pegaspargase 2500IU/㎡d1, repeated every 3 weeks) regimen combined with radiotherapy (≥50Gy), either sequential or sandwich chemoradiation. Response to treatment was evaluated using MRI scan or PET-CT scan after chemotherapy and end of treatment. Progression free survival (PFS) was calculated from diagnosis of ENKTCL to disease progression, death of any reason, or last follow-up, whichever came first. Overall survival (OS) was defined from diagnosis to death of any reason, or last follow-up, whichever came first. The institutional ethics review board approved this study and all patients provided informed consent for publication of clinical data at their first visit, but all patients in this study had been de-identified. Moreover, we identified 1140 patients with ENKTCL from the SEER database ([www.seer.cancer.gov](http://www.seer.cancer.gov)) based on the ICD-O-3 code for histology (9719, ENKTCL) during 1987 to 2015, and 330 patients were excluded from our analysis due to unknown stage or missing detailed survival data.

68 patients with early stage ENKTCL received GELOX induction therapy and 125 patients were treated with EPOCHL regimen. No significant difference was found between those two groups concerning baseline characteristics. At the end of treatment, a complete response (CR) rate of 75% and overall response rate (ORR) of 98.5% was achieved in the GELOX group, and the CR rate and ORR was 56% and 94.4% in the EPOCHL group, respectively. Although there was no significant difference in ORR between GELOX and EPOCHL regimen, as is shown in Figure 1, patients treated with GELOX had significantly better PFS and OS than those with EPOCHL (p<0.05). Meanwhile, the safety profile of GELOX regimen was more favorable than EPOCHL, especially the hematology toxicities. As expected, patients with stage II disease had significantly inferior outcomes than those with stage I disease (p<0.05). The end of treatment efficacy had significant impact on the long-term survival outcomes, as patients with CR enjoyed more favorable PFS and OS than those without CR (p<0.05). In the GELOX cohort, efficacy assessment data was available before RT consolidation. As is shown in Figure 1-H, patients without CR after induction chemotherapy had significantly inferior PFS than those with CR (p=0.033), though part of those patients could be salvaged by RT consolidation and attained CR at the end of RT.



Figure 1. Survival curves for ENKTCL patients with localized disease. Patients treated with GELOX regimen had significantly better OS (A) and PFS (B) than those treated with EPOCHL. Patients with stage II disease had significantly inferior OS (C) and PFS (D) than those with stage I. The end of treatment response significantly correlated with prognosis of ENKTCL (E, F). For patients treated with GELOX, CR before radiotherapy indicated significantly better PFS (H) and a trend for better OS (G). CR means complete response, RT means radiotherapy.

The detailed baseline characteristics of both Chinese and SEER cohorts were shown in Table 1. More patients in the SEER database were treated before 2010, when asparaginase-based therapies were not well recognized. Moreover, significantly more patients in the SEER database had extra-nasal or non-upper aerodigestive tract (UADT) disease. The treatment strategies were unknown for the SEER database, and asparaginase-based chemotherapy with or without combined radiotherapy were administrated in the Chinese cohort. As is shown in Figure 2, the five-year OS rate was 79.4%, 56.6%, and 43.6% for patients with stage I, II, and III-IV, respectively, in the Chinese cohort, which seemed much better than that in the SEER database (55.2%, 35.6%, and 21.2%, respectively). This discrepancy may caused by unbalanced baseline characteristics and different treatment strategies. Also, the etiology and biology of ENKTCL may differ between Asian and Western countries.

Table 1. The baseline characteristics of ENKTCL patients.

|  |  |  |  |
| --- | --- | --- | --- |
|  | Chinese cohort  (N=494) | SEER database  (N=810) | P value |
| Year of diagnosis |  |  |  |
| 1987-2009 | 191 (38.7%) | 443 (54.7%) | **P <0 .001** |
| 2010-now | 303 (61.3%) | 367 (45.3%) |
| Gender |  |  |  |
| Male | 335 (67.8%) | 524 (64.7%) | P = 0.274 |
| Female | 159 (32.2%) | 286 (35.3%) |
| Age |  |  |  |
| ＜60 | 403 (81.6%) | 513 (63.3%) | **P <0 .001** |
| ≥60 | 91 (18.4%) | 297 (36.7%) |
| Ann-Arbor stage |  |  |  |
| I | 179 (36.2%) | 381 (47.0%) | **P <0 .001** |
| II | 197 (39.9%) | 179 (22.1%) |
| III-IV | 118 (23.9%) | 250 (30.9%) |
| Primary lymphoma site |  |  |  |
| UADT | 452 (91.5%) | 596 (73.6%) | **P <0 .001** |
| Non-UADT | 42 (8.5%) | 214 (26.4%) |
| Nasal cavity | 320 (64.8%) | 387 (47.8%) | **P <0 .001** |
| Extra-nasal sites | 174 (35.2%) | 423 (52.2%) |



Figure 2. Survival curves for patients of ENKTCL in the Chinese (A) and SEER (B) cohorts. AASS means Ann-Arbor staging system.

Due to the distinct geographic pattern of ENKTCL, many studies were done in Asian countries, and asparaginase-based induction therapies were well recognized, should be given in the first-line setting. Nowadays, risk-model guided therapy should be implemented in clinical practice[5]. For those localized disease at low-risk, radiotherapy alone could achieve satisfactory results, and asparaginase-based chemotherapy should be added to radiotherapy for those with risk factors. The standard induction regimens were not defined yet, and our previous study demonstrated that pegaspargase monotherapy in combination with concurrent radiotherapy could attain 100% CR rate for early stage disease[6], which needs to be validated in phase 3 RCTs. Although the prognosis is much better for Chinese cohort, patients with advanced disease still fare poorly. Increasing evidence has shown the advantage of immunotherapy (PD-1/PD-L1 blockade) in relapsed/refractory ENKTCL[7], and we guess the first-line use of immunotherapy in combination with asparaginase-based chemotherapy might further improve the prognosis of patients with advanced disease[8]. Recently, a novel molecular subtyping system was defined for ENKTCL, including TSIM, MB, and HEA subtypes, with both prognostic value and treatment guidance[9]. In future, prospective clinical trials should be conducted incorporating the new risk models and molecular subtyping system, to further implement precision medicine in ENKTCL.

**Conflict of interest**

The authors declared no conflict of interest.

**References**

1. Wang L, Li LR, Zhang L, Wang JW. The landscape of new drugs in extranodal NK/T-cell lymphoma. Cancer Treat Rev. 2020;89:102065. doi: 10.1016/j.ctrv.2020.102065. PubMed PMID: 32653806.

2. Wang L, Wang ZH, Chen XQ, Li YJ, Wang KF, Xia YF, et al. First-line combination of gemcitabine, oxaliplatin, and L-asparaginase (GELOX) followed by involved-field radiation therapy for patients with stage IE/IIE extranodal natural killer/T-cell lymphoma. Cancer. 2013;119(2):348-55. doi: 10.1002/cncr.27752. PubMed PMID: 22811078.

3. Wei L, Wang J, Ye J, Yang L, Cong J, Li X, et al. Long-term outcomes of patients treated with an EPOCHL regimen as first-line chemotherapy for newly diagnosed extranodal natural killer/T-cell lymphoma: a retrospective single-center study. Leuk Lymphoma. 2020;61(2):337-43. doi: 10.1080/10428194.2019.1663421. PubMed PMID: 31517553.

4. Fox CP, Civallero M, Ko YH, Manni M, Skrypets T, Pileri S, et al. Survival outcomes of patients with extranodal natural-killer T-cell lymphoma: a prospective cohort study from the international T-cell Project. Lancet Haematol. 2020. doi: 10.1016/S2352-3026(19)30283-2. PubMed PMID: 32105608.

5. Chen SY, Yang Y, Qi SN, Wang Y, Hu C, He X, et al. Validation of nomogram-revised risk index and comparison with other models for extranodal nasal-type NK/T-cell lymphoma in the modern chemotherapy era: indication for prognostication and clinical decision-making. Leukemia. 2020. doi: 10.1038/s41375-020-0791-3. PubMed PMID: 32152465.

6. Wang H, Wang L, Li C, Wuxiao Z, Chen G, Luo W, et al. Pegaspargase Combined with Concurrent Radiotherapy for Early-Stage Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type: A Two-Center Phase II study. Oncologist. 2020. doi: 10.1634/theoncologist.2020-0144. PubMed PMID: 32627928.

7. Wang L, Wang JW. PD-1 blockade in extranodal NK/T-cell lymphoma: who is in charge? Leukemia. 2020. doi: 10.1038/s41375-020-01046-8. PubMed PMID: 33009482.

8. Wang L, Wang JW. Extranodal natural-killer T-cell lymphoma: experience from China. Lancet Haematol. 2020;7(6):e441. doi: 10.1016/S2352-3026(20)30103-4. PubMed PMID: 32470431.

9. Xiong J, Cui BW, Wang N, Dai YT, Zhang H, Wang CF, et al. Genomic and Transcriptomic Characterization of Natural Killer T Cell Lymphoma. Cancer Cell. 2020;37(3):403-19 e6. doi: 10.1016/j.ccell.2020.02.005. PubMed PMID: 32183952.